NCT05984823Completed
Home-based Body Weight Exercise With Blood Flow Restriction (BFR): Feasibility of a Novel Rehabilitation Intervention in COPD Patients (HomeBFR-COPD)
Home-based Body Weight Exercise With Blood Flow Restriction (BFR): Feasibility of a Novel Rehabilitation Intervention in COPD Patients
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
The primary aim of this randomised controlled trial is to investigate the feasibility and acceptability of low-intensity exercise with blood flow restriction (BFR) in patients with Chronic Obstructive Pulmonary disease (COPD). The investigators will also collect functional and physiological outcome data to explore potential mechanisms and provide data for a power calculation to be used in a future randomised controlled trial (RCT) to ensure that subsequent full scale clinical RCT has maximum reach and benefit. The primary experimental hypothesis that underpins these aims is: • Low-intensity exercise with BFR is a tolerable, acceptable, and safe exercise modality in COPD patients. 40 patients attending clinics at University Hospitals of Leicester (UHL) National Health Service (NHS) Trust with diagnosed COPD will be randomly allocated to a home-based body weight exercise intervention either with or without the blood flow restriction (n=20 in each group). The body weight exercise will consist of five body weight exercises including: sitting knee extensions, standing knee raise, heel-toe raises, bilateral mini-squat behind a chair, and chair rise/sit to stand. In addition to the pre and post intervention visits, the initial two training sessions for both groups will be directly supervised in the research centre. These sessions are to ensure all exercises are performed correctly and safely and the patient become familiar with the exercises and BFR equipment and mobile application, which provides exercise guidance and session recording.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 13 Jul 2023
- Start date
- 26 Jan 2024
- Primary completion date
- 4 Nov 2024
- Lead sponsor
- Mrs Hanoof Aljohani
- Diseases
- COPD
- NCT number
- NCT05984823
What you commit to
- Study type: Interventional
- Participants enrolled: 27
- From 26 Jan 2024 to the primary completion date, 4 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Scheduled elective surgery or other procedures requiring general anaesthesia during the study.
Other illness
- Any major or uncontrolled comorbidity that would impair the participant's ability to exercise or would mean exercise was unsafe (e.g., uncontrolled diabetes, hypertension BP\>160/100, muscle or joint injuries which would limit ability to exercise).
- Any other significant disease, disorder, or medical condition which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study including (but not limited to):
- Any clotting disorder Any bleeding disorder (e.g., haemophilia) Recent (\<3 months) venous thromboembolism, vascular (artery or vein) surgery to the legs, skin graft to the legs, and or arteriovenous fistula in the legs.
- Had one or both legs immobilisation in the last 4 weeks (e.g., prolonged bed rest, or recent orthopaedic intervention) Taking any anticoagulant medication Significant peripheral neuropathy
Other
- Unable to communicate sufficiently in English
- Unable to give informed consent or comply with testing and training protocol for any reason.
- Acute exacerbation in the preceding 4 weeks (would become eligible 4 weeks following recovery).
- Unable to undertake exercise due to physical or psychological barriers.
- Contraindication to exercise training (American College of Sports Medicine guidelines)
- Current or within the last 3 months (or maximum relevant wash out period, whichever is longer), participation in an investigational medicinal product (IMP) or device trial at the time of screening.
- Current or within the last 6 months (or maximum relevant wash out period, whichever is longer), participation in pulmonary rehabilitation or in another research study involving exercise training.
- Female participants who are pregnant, lactating, or planning pregnancy during the course of the study.
Who the study is looking for
- Male or Female
- Aged 40 years or above
- Diagnosed with COPD as per GOLD criteria (Forced expiratory volume(FEV1)/forced vital capacity(FVC) \<0.7)
- FEV1 ≤ 80% predicted
- Medical Research Council (MRC) dyspnoea scale ≥2
- BMI \<= 35
- Willing and able to give informed consent for participation in the study.
- Stable dose of current regular medication for at least 4 weeks prior to study entry.
- Clinically acceptable ECG at enrolment.
- Able (in the investigators opinion) and willing to comply with all study requirements.
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NIHR Leicester Biomedical Research Centre - Respiratory Coordinator of this site? Confirm its status | Leicester | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.